Economy/Home · Economy

MedPacto Receives FDA Approval for Phase 1/2 Trial Protocol Amendment for Osteosarcoma Treatment 'Bectoseptip'... Exploring Optimal Dose of 200mg vs 300mg

MedPacto announced in a regulatory filing on the 19th that it has received approval from the U.S. Food and Drug Administration (FDA) for an amendment to the Investigational New Drug (IND) application for its U.S. Phase 1/2 clinical trial of 'Bectoseptip' monotherapy in patients with relapsed, refrac

Oseong Kwon
Staff Reporter
5 min read
MedPacto Receives FDA Approval for Phase 1/2 Trial Protocol Amendment for Osteosarcoma Treatment 'Bectoseptip'... Exploring Optimal Dose of 200mg vs 300mg
CBC News

MedPacto announced in a regulatory filing on the 19th that it has received approval from the U.S. Food and Drug Administration (FDA) for an amendment to the Investigational New Drug (IND) application for its U.S. Phase 1/2 clinical trial of 'Bectoseptip' monotherapy in patients with relapsed, refractory, or progressive osteosarcoma.

According to the filing, the company applied for the protocol amendment with the FDA on September 18, and the amendment was approved on October 19. MedPacto said it was informed by its agent on that day that the clinical trial may proceed in accordance with FDA guidance.

◆ 200mg vs 300mg... Goal Is to Determine the Optimal Dose

The amendment is intended to determine the optimal dose through an exploratory comparison of the efficacy and safety of a 200mg twice-daily dose group and a 300mg twice-daily dose group of Bectoseptip.

The trial is an open-label, multicenter Phase 1/2 clinical trial evaluating the safety, tolerability, pharmacokinetics, and antitumor activity of Bectoseptip monotherapy in adolescent and adult patients with relapsed, refractory, or progressive osteosarcoma. The site listed in the filing is UH Rainbow Babies and Children's Hospital at Case Western Reserve University in the United States.

◆ Phase 1 to Evaluate Safety and Tolerability, Phase 2 to Assess Antitumor Activity

In Phase 1, safety and tolerability will be evaluated, including the determination of the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) based on the occurrence of dose-limiting toxicities (DLT). The primary evaluation endpoints are the DLT incidence rate and the incidence and severity of adverse events.

In Phase 2, the company plans to confirm the antitumor activity of Bectoseptip monotherapy and evaluate the association between biomarkers and clinical benefit in each dose group. The primary endpoint is the objective response rate (ORR) according to RECIST 1.1 criteria.

◆ Number of Subjects, Timeline, and Regulatory Approval Likelihood

The target number of subjects is a minimum of 9 adults and up to 9 adolescents in Phase 1, and a minimum of 42 adults and adolescents per dose group in Phase 2. The first subject enrollment date is May 1, 2023, and the expected completion date is February 29, 2028. MedPacto noted that the expected completion date may change depending on the pace of subject enrollment.

The company also cautioned that the probability of a clinical trial drug ultimately receiving drug approval is statistically known to be around 10%, and that commercialization plans may be altered or abandoned depending on the outcomes of the clinical trial and product approval process.

Oseong Kwon
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.